Recent Advances in Evaluating Impact of Biologic Therapy for Moderate-Severe Psoriasis on Cardiovascular Events and Atherosclerotic Plaque Formation

Abstract

Keywords

psoriasis cardiovascular disease biologic therapy atherosclerotic plaque IL-17A IL-17 TNF-alpha IL-23 acute coronary syndrome coronary computed tomography angiography (CCTA)fat attenuation index (FAI)

Get full access to this article

View all access options for this article.

References

SC.

Lan

. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):E2211.doi:10.3390/ijms18102211

Fahim

Kim

BW.

Bourcier

et al. Checklist for the systemic treatment of psoriasis using biologics: a Delphi study. J Cutan Med Surg. 2019;23(3):282-288.doi:10.1177/1203475419833605

Elnabawi

YA.

Oikonomou

EK.

Dey

et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol. 2019;4(9):885.doi:10.1001/jamacardio.2019.2589

Elnabawi

YA.

Dey

AK.

Goyal

et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721-728.doi:10.1093/cvr/cvz009

von Stebut

Reich

Thaçi

et al. Impact of Secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054-1062.doi:10.1016/j.jid.2018.10.042